An observational study in Head & Neck Cancer and Head & Neck Squamous Cell Carcinoma, sponsored by University of Rome Tor Vergata. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by University of Rome Tor Vergata · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy — 44 open to participants now, 62 under way, 13 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Italy.
Among the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy, this one is the 19th largest by planned enrollment of the 20 observational ones that give a count, is one of 16 that started in 2024, is one of 20 observational ones, reaches primary completion later than 23 of the 61 other live ones, and was the 122nd registered.
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →44 of the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy are open now. Recruiting first, the newest first:
Corbus Pharmaceuticals Inc. · Sites in Italy, United States, Austria and 11 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Italy, United States, Australia and 3 more countries
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in Italy
Ages 18+
Janssen Research & Development, LLC · Sites in Italy, United States, Australia and 19 more countries
Ages 18+
Fondazione del Piemonte per l'Oncologia · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
129 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 54 · Phase 3 36
First in 1992; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 100 across 237 observational studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 194 across the 109 interventional studies, 135 across the 20 observational. Of the 60 that completed or were terminated, 33 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 129 have an industry lead sponsor. The 10 most frequent:
University of Rome Tor Vergata is the lead sponsor of 96 studies on the registry; 20 are open to participants now.
University of Rome Tor Vergata has 1 study filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
17 of the studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05815927Phase 3European Organisation for Research and Treatment of Cancer - EORTCPembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer | 2027-07-15 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT07448727University of Rome Tor VergataImpact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT | 2026-12-31 |
| NCT05621837Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoQuantifying Systemic Immunosuppression to Personalize Cancer Therapy | 2026-12-31 |
| NCT07949526IRCCS San RaffaeleCompressive Dressing and Pharyngocutaneous Fistula After Primary Total Laryngectomy | 2027-01-05 |
Add all 17 to your calendar (.ics) → With an account.
Among the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS >1 treated with pembrolizumab monotherapy, in accordance with routine clinical practice.
Eligible patients will receive two administrations of Pembrolizumab as monotherapy.
An 18F-FDG PET/CT scan will be performed at baseline (T0; no more than 30 days before the first drug administration) and after two cycles (T1, at 6 weeks).
Patients will be considered responders if they achieve a complete response (defined as complete resolution of FDG uptake within the target lesions) or a partial response (i.e., >=30% decrease in the target tumor FDG SULpeak).
After the first two administrations of Pembrolizumab, as well as in case of progressive disease (i.e., >=30% increase in the target tumor FDG SULpeak or advent of new 18FDG-avid lesions), any treatment modification will be determined by the physician according to routine clinical practice
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
This study's planned enrollment of 25 is below the median of 100 across 237 observational studies indexed under Squamous Cell Carcinoma of Head and Neck.
Browse Squamous Cell Carcinoma of Head and Neck studies →University of Rome Tor Vergata is the lead sponsor of 96 studies on the registry; 20 are open to participants now.
Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
recurrent and/or metastatic HNSCC candidate for ICI-based first-line treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Predictive value of 18F-FDG PET/CT metabolic changes at 6 weeks for response to pembrolizumab
To evaluate whether changes in metabolic activity on 18F-FDG PET/CT at 6 weeks predict response to pembrolizumab monotherapy at 3, 6, and 9 months in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC).
Time frame: through study completion, an average of 1 year
Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.
Of 107 non-industry observational studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 132. This study's planned 25 months is below that.
Counting every sponsor, half of 117 studies reached it within 77 months; a quarter within 26 and three quarters within 132.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Squamous Cell Carcinoma of Head and Neck →
University of Rome Tor Vergata